Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 9/20 | 0.47 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.47 |
| ▸ | VEGFA | P15692 | 1/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18459334 | 1.00 | RAB9A (0.47) | RAB9AALDH1A1HTTL3MBTL1NPC1 | |
| SCHEMBL21399862 | 0.84 | MAPT (0.48) | RAB9AALDH1A1HTTL3MBTL1NPC1 | |
| SCHEMBL21378605 | 0.84 | MAPT (0.53) | RAB9AALDH1A1HTTL3MBTL1NPC1 | |
| SCHEMBL21378603 | 0.84 | MAPT (0.53) | RAB9AALDH1A1HTTL3MBTL1NPC1 | |
| SCHEMBL21378470 | 0.83 | ACACB (0.52) | RAB9AALDH1A1HTTACACBPOLB | |
| SCHEMBL21378468 | 0.83 | ACACB (0.52) | RAB9AALDH1A1HTTACACBPOLB | |
| SCHEMBL19700726 | 0.83 | MAPT (0.45) | RAB9AALDH1A1HTTL3MBTL1NPC1 | |
| SCHEMBL19700725 | 0.83 | MAPT (0.45) | RAB9AALDH1A1HTTL3MBTL1NPC1 | |
| SCHEMBL21378569 | 0.83 | MAPT (0.45) | RAB9AALDH1A1HTTL3MBTL1NPC1 | |
| SCHEMBL20289586 | 0.83 | MAPT (0.45) | RAB9AALDH1A1HTTL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109311863-B | Mutant IDH1 inhibitors | 伊莱利利公司 | 2021-10-29 | — | — | CN | disclosed |
| EP-3464281-B1 | MUTANT IDH1 INHIBITORS | LILLY CO ELI (US) | 2020-07-08 | — | — | EP | disclosed |
| US-10696665-B2 | Mutant IDH1 inhibitors | ELI LILLY AND COMPANY (US) | 2020-06-30 | — | — | US | disclosed |
| CN-107849059-B | 7-phenylethylamino-4H-pyrimido [4,5-D ] [1,3] oxazin-2-one compounds and their use as inhibitors of mutant IDH1 | 伊莱利利公司 | 2020-04-28 | — | — | CN | disclosed |
| EP-3328866-B1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AND THEIT USE AS MUTANT IDH1 INHIBITORS | LILLY CO ELI (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20190292175-A1 | MUTANT IDH1 INHIBITORS | ELI LILLY AND COMPANY | 2019-09-26 | — | — | US | disclosed |
| US-10253041-B2 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds and their use as mutant IDH1 inhibitors | ELI LILLY AND COMPANY (US) | 2019-04-09 | — | — | US | disclosed |
| US-20180118759-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AND THEIR USE AS MUTANT IDH1 INHIBITORS | ELI LILLY AND COMPANY | 2018-05-03 | — | — | US | disclosed |
| WO-2017213910-A1 | MUTANT IDH1 INHIBITORS | ELI LILLY AND COMPANY (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017019429-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AND THEIT USE AS MUTANT IDH1 INHIBITORS | ELI LILLY AND COMPANY (US) | 2017-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696665-B2 | Mutant IDH1 inhibitors | IDH1, IDH3B, IDH3A | RAB9A 2114/4885ALDH1A1 260/4885HTT 1352/4885 |
| US-20190292175-A1 | MUTANT IDH1 INHIBITORS | IDH1, IDH3B, IDH3A | RAB9A 2114/4885ALDH1A1 260/4885HTT 1352/4885 |
| US-10253041-B2 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds and their use as mutant IDH1 inhibitors | IDH1, IDH3A, IDH3B | RAB9A 3500/4885ALDH1A1 17/4885HTT 724/4885 |
| US-20180118759-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AND THEIR USE AS MUTANT IDH1 INHIBITORS | IDH1, IDH3A, IDH3B | RAB9A 3500/4885ALDH1A1 17/4885HTT 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.